Defining metabolic targets in kidney cancer for new treatments
Official title: Project 2: Defining Targetable Metabolic Dependencies in Human Renal Cell Carcinoma
Funded at Ut Southwestern Medical Center · NIH-11400752 · Data updated 2026-11-12
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | August 1, 2016 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $357,520 |
| NIH project number | 5P50CA196516-10 |
| Project ID | NIH-11400752 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with clear cell renal cell carcinoma or related kidney cancers who may undergo metabolism-based studies and participate in translational research.
✕Less likely to help
Patients not eligible for tumor metabolism studies or those without ccRCC may not benefit directly.
What this research studies
This project studies how metabolic changes drive clear cell renal cell carcinoma (ccRCC) and aims to identify enzymes that could be blocked with easy-to-use drugs. Researchers have tested methods in humans to observe how RCC processes nutrients and energy, and they are developing models that closely mirror human tumors. A translational platform called the In Vivo Metabolism Lab helps connect patient metabolism data to potential therapies. The work spans several years and includes advanced patient-derived tumor models to test promising targets.
Why it matters
Potential benefit: If successful, patients with ccRCC could gain new targeted treatment options based on their tumor metabolism.
How similar studies have gone: Previous work shows that patient-derived tumor models and metabolic profiling can reveal actionable targets, supporting potential success for similar approaches.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Deberardinis, Ralph J — Ut Southwestern Medical Center
- Study coordinator: Deberardinis, Ralph J
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
-
How mitochondrial activity and cancer spread are affected by tRNA changes in kidney cancer
This project looks at how specific tRNA modifications influence mitochondrial function and the spread of kidney cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.